<<WATCH>>
GDDY--
INO--
Interesting Angle) Funding from Gov
Inovio hasn't received a large funding commitment from the U.S. government's Operation Warp Speed (OWS) program so far. However, the company is farther along in clinical testing with INO-4800 than some other drugmakers that have received significant funding from OWS. One potential reason why that's the case is that in the past Inovio's capacity for manufacturing INO-4800 was only a fraction of the capacity of others in the race to develop coronavirus vaccines.
Now, though, Inovio's deal with Thermo Fisher Scientific could change the dynamics. The capability to produce 100 million doses of INO-4800 just might catch the attention of OWS or the governments of other countries hoping to secure COVID-19 vaccines.
At the same time, the potential safety issue with AstraZeneca's COVID-19 vaccine candidate could spur OWS to consider adding another investigational vaccine to its roster of funded programs. The U.S.committed $1.2 billion in funding to the big drugmaker in May to secure 300 million doses of AZD1222.
GDDY--
INO--
Interesting Angle) Funding from Gov
Inovio hasn't received a large funding commitment from the U.S. government's Operation Warp Speed (OWS) program so far. However, the company is farther along in clinical testing with INO-4800 than some other drugmakers that have received significant funding from OWS. One potential reason why that's the case is that in the past Inovio's capacity for manufacturing INO-4800 was only a fraction of the capacity of others in the race to develop coronavirus vaccines.
Now, though, Inovio's deal with Thermo Fisher Scientific could change the dynamics. The capability to produce 100 million doses of INO-4800 just might catch the attention of OWS or the governments of other countries hoping to secure COVID-19 vaccines.
At the same time, the potential safety issue with AstraZeneca's COVID-19 vaccine candidate could spur OWS to consider adding another investigational vaccine to its roster of funded programs. The U.S.committed $1.2 billion in funding to the big drugmaker in May to secure 300 million doses of AZD1222.